| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |

From the Department of Medicine,*
New York Medical
College, Valhalla, New York; and the Istituto di Ricerche
Farmacologiche Mario Negri,
Milano, Italy
To determine whether up-regulation of AT1 and AT2 receptors occurred in hypertrophied myocytes after infarction and whether AT2 played a role in stretch-mediated apoptosis, left ventricular myocytes were dissociated from the surviving portion of the wall 8 days after coronary occlusion and cardiac failure in rats. Control cells were obtained from sham-operated animals. Myocytes were stretched in an equibiaxial stretch apparatus and angiotensin II (Ang II) formation and cell death were measured 3 and 12 hours later. AT1 and AT2 proteins were evaluated in freshly isolated myocytes and after stretch. The effects of AT1 and AT2 antagonists on stretch-induced Ang II synthesis and apoptosis were also established. Myocardial infarction increased AT1 and AT2 in myocytes and stretch further up-regulated these receptors. Ang II levels were higher in postinfarcted myocytes and this peptide increased with the duration of stretch in both groups of cells. Similarly, apoptosis increased with time in control and postinfarcted myocytes. Absolute values of Ang II and apoptosis were greater in myocytes from infarcted hearts at 3 and 12 hours after stretch. Addition of AT1 blocker to cultures inhibited stretch-activated apoptosis in both myocyte populations as well as the generation of Ang II in postinfarcted myocytes. In contrast, AT2 antagonists had no impact on these cellular events. In conclusion, Ang II stimulated cell death through AT1 receptor activation, whereas ligand binding to AT2 receptor did not alter Ang II concentration and apoptosis in normal and postinfarcted hypertrophied myocytes.
This article has been cited by other articles:
![]() |
J. Xu, O. A. Carretero, C.-X. Lin, M. A. Cavasin, E. G. Shesely, J. J. Yang, T. L. Reudelhuber, and X.-P. Yang Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1900 - H1907. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Kasama, T Toyama, T Hatori, H Sumino, H Kumakura, Y Takayama, S Ichikawa, T Suzuki, and M Kurabayashi Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure Heart, May 1, 2006; 92(5): 625 - 630. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Brunton A positive feedback loop contributes to the deleterious effects of angiotensin PNAS, October 11, 2005; 102(41): 14483 - 14484. [Full Text] [PDF] |
||||
![]() |
B. Ding, J.-i. Abe, H. Wei, H. Xu, W. Che, T. Aizawa, W. Liu, C. A. Molina, J. Sadoshima, B. C. Blaxall, et al. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis PNAS, October 11, 2005; 102(41): 14771 - 14776. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Leri, J. Kajstura, and P. Anversa Cardiac Stem Cells and Mechanisms of Myocardial Regeneration Physiol Rev, October 1, 2005; 85(4): 1373 - 1416. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-D. Wang, X.-Y. Wang, H.-Z. Hu, X.-C. Fang, S. Liu, N. Gao, Y. Xia, and J. D. Wood Angiotensin receptors and actions in guinea pig enteric nervous system Am J Physiol Gastrointest Liver Physiol, September 1, 2005; 289(3): G614 - G626. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tan, H. Wang, and F. H. H. Leenen Increases in brain and cardiac AT1 receptor and ACE densities after myocardial infarct in rats Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1665 - H1671. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tzanidis, R. D. Hannan, W. G. Thomas, D. Onan, D. J. Autelitano, F. See, D. J. Kelly, R. E. Gilbert, and H. Krum Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy Circ. Res., August 8, 2003; 93(3): 246 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Addition of Valsartan to an Angiotensin-Converting Enzyme Inhibitor Improves Cardiac Sympathetic Nerve Activity and Left Ventricular Function in Patients with Congestive Heart Failure J. Nucl. Med., June 1, 2003; 44(6): 884 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Ratcliffe Non-ischemic infarct extension: A new type of infarct enlargement and a potential therapeutic target J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1168 - 1171. [Full Text] [PDF] |
||||
![]() |
W. G. Thomas, Y. Brandenburger, D. J. Autelitano, T. Pham, H. Qian, and R. D. Hannan Adenoviral-Directed Expression of the Type 1A Angiotensin Receptor Promotes Cardiomyocyte Hypertrophy via Transactivation of the Epidermal Growth Factor Receptor Circ. Res., February 8, 2002; 90(2): 135 - 142. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Cohn, G. Tognoni, and the Valsartan Heart Failure Trial Investigators A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure N. Engl. J. Med., December 6, 2001; 345(23): 1667 - 1675. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Dalla Libera, B. Ravara, A. Angelini, K. Rossini, M. Sandri, G. Thiene, G. Battista Ambrosio, and G. Vescovo Beneficial Effects on Skeletal Muscle of the Angiotensin II Type 1 Receptor Blocker Irbesartan in Experimental Heart Failure Circulation, May 1, 2001; 103(17): 2195 - 2200. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Barlucchi, A. Leri, D. E. Dostal, F. Fiordaliso, H. Tada, T. H. Hintze, J. Kajstura, B. Nadal-Ginard, and P. Anversa Canine Ventricular Myocytes Possess a Renin-Angiotensin System That Is Upregulated With Heart Failure Circ. Res., February 16, 2001; 88(3): 298 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. G. Thomas, Y. Brandenburger, D. J. Autelitano, T. Pham, H. Qian, and R. D. Hannan Adenoviral-Directed Expression of the Type 1A Angiotensin Receptor Promotes Cardiomyocyte Hypertrophy via Transactivation of the Epidermal Growth Factor Receptor Circ. Res., February 8, 2002; 90(2): 135 - 142. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |